NEW YORK, NY / ACCESSWIRE / July 17, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Mallinckrodt plc (“Mallinckrodt” or the Company”) (NYSE: MNK). Investors who purchased Mallinckrodt securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: www.bgandg.com/mnk.
The investigation concerns whether Mallinckrodt and certain of its officers and/or directors have violated federal securities laws.
On July 16, 2019, post-market, Mallinckrodt announced that the Company “is permanently discontinuing its Phase 2B study designed to assess the efficacy and safety of Acthar® Gel (repository corticotropin injection) as an investigational treatment for amyotrophic lateral sclerosis (ALS).” Mallinckrodt stated that it decided “to halt the trial after careful consideration of a recent recommendation by the study’s independent Data and Safety Monitoring Board (DSMB)” which “was based on the specific concern for pneumonia, which occurred at a higher rate in the ALS patients receiving Acthar Gel compared to those on placebo” and that “the board also mentioned other adverse events specific to this patient population.” On this news, Mallinckrodt’s stock price fell sharply during intraday trading on July 17, 2019.
If you are aware of any facts relating to this investigation, or purchased Mallinckrodt shares,you can assist this investigation by visiting the firm’s site: www.bgandg.com/mnk. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]
SOURCE: Bronstein, Gewirtz & Grossman, LLC